@article{ATM24939,
author = {Joshua M. Bauml and Charu Aggarwal and Roger B. Cohen},
title = {Immunotherapy for head and neck cancer: where are we now and where are we going?},
journal = {Annals of Translational Medicine},
volume = {7},
number = {Suppl 3},
year = {2019},
keywords = {},
abstract = {Head and neck squamous cell carcinoma (HNSCC) is a relatively common cancer (1). While many patients with locally advanced disease are cured with some combination of surgery, radiation, and chemotherapy, others will develop recurrent/metastatic disease (R/M) and are considered incurable. Cytotoxic chemotherapy has limited efficacy and substantial toxicity in metastatic HNSCC, with a median overall survival of less than a year (2).},
issn = {2305-5847}, url = {https://atm.amegroups.org/article/view/24939}
}